INM
NASDAQ · Pharmaceuticals
Inmed Pharmaceuticals Inc
$1.55
+0.05 (+3.33%)
Financial Highlights (FY 2026)
Revenue
16.78M
Net Income
-27,714,846
Gross Margin
34.5%
Profit Margin
-165.1%
Rev Growth
+65.6%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 34.5% | 34.5% | 36.7% | 36.7% |
| Operating Margin | -160.8% | -144.7% | 22.2% | 22.3% |
| Profit Margin | -165.1% | -156.9% | 21.8% | 17.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 16.78M | 10.14M | 790.8K | 761.6K |
| Gross Profit | 5.80M | 3.50M | 290.3K | 279.5K |
| Operating Income | -26,983,299 | -14,669,265 | 175.2K | 169.9K |
| Net Income | -27,714,846 | -15,066,965 | 172.0K | 136.0K |
| Gross Margin | 34.5% | 34.5% | 36.7% | 36.7% |
| Operating Margin | -160.8% | -144.7% | 22.2% | 22.3% |
| Profit Margin | -165.1% | -156.9% | 21.8% | 17.9% |
| Rev Growth | +65.6% | +65.6% | +11.4% | +19.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 119.3K | 118.2K |
| Total Equity | — | — | 1.24M | 1.28M |
| D/E Ratio | — | — | 0.10 | 0.09 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -26,260,304 | -15,069,337 | 218.3K | 221.4K |
| Free Cash Flow | — | — | 109.5K | 116.5K |